

AVANIR PHARMACEUTICALS, INC.

Form 8-K

January 10, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 6, 2014**

**Avanir Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**001-15803**  
**(Commission File Number)**

**33-0314804**  
**(I.R.S. Employer**  
**Identification No.)**

**20 Enterprise, Suite 200, Aliso Viejo, California**  
**(Address of principal executive offices)**

**92656**  
**(Zip Code)**

**Registrant's telephone number, including area code: (949) 389-6700**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 6, 2014, Scott M. Whitcup, M.D. resigned from the Board of Directors of Avanir Pharmaceuticals, Inc. (the Company). Prior to his resignation, Dr. Whitcup served as Chairman of the Science Committee and as a member of each of the Corporate Governance Committee and Executive Committee. Dr. Whitcup's resignation was not caused by a disagreement with the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 10, 2014

Avanir Pharmaceuticals, Inc.

By: /s/ Christine G. Ocampo  
Christine G. Ocampo  
Vice President, Finance

-3-